Recurrent cervical carcinoma Trials in Mentor, United States
Conditions / Recurrent cervical carcinoma / Mentor, United States
Recurrent cervical carcinoma has been the subject of sustained clinical investigation across multiple research sites.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02257528 | Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT00217633 | Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer | COMPLETED | PHASE2 |
| NCT00803062 | Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer | COMPLETED | PHASE3 |
| NCT00309959 | ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer | COMPLETED | PHASE2 |
| NCT01266460 | Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer | COMPLETED | PHASE2 |
| NCT01267253 | Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer | COMPLETED | PHASE2 |
| NCT01098630 | Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer | COMPLETED | — |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | ACTIVE_NOT_RECRUITING | — |
| NCT00897442 | Collecting Tumor Samples From Patients With Gynecological Tumors | COMPLETED | — |
| NCT01266447 | Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer | COMPLETED | PHASE2 |